» Articles » PMID: 11796549

Value of Plasma B Type Natriuretic Peptide Measurement for Heart Disease Screening in a Japanese Population

Overview
Journal Heart
Date 2002 Jan 18
PMID 11796549
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Conflict exists regarding the usefulness of measuring plasma B type natriuretic peptide (BNP) concentrations for identifying impaired left ventricular (LV) systolic function during mass screening. Various cardiac abnormalities, regardless of degree of LV dysfunction, are prone to carry a high risk of cardiovascular events.

Objective: To examine the validity of plasma BNP measurement for detection of various cardiac abnormalities in a population with a low prevalence of coronary heart disease and LV systolic dysfunction.

Design And Setting: Participants in this cross sectional study attended a health screening programme in Iwate, northern Japan. Plasma BNP concentrations were determined in 1098 consecutive subjects (mean age 56 years) by direct radioimmunoassay. All subjects underwent multiphasic health checkups including physical examination, ECG, chest radiography, and transthoracic echocardiography.

Results: Conventional diagnostic methods showed 39 subjects to have a wide range of cardiac abnormalities: lone atrial fibrillation or flutter in 11; previous myocardial infarction in seven; valvar heart disease in seven; hypertensive heart disease in six; cardiomyopathy in six; atrial septal defect in one; and cor pulmonale in one. No subjects had a low LV ejection fraction (< 40%). To assess the utility of plasma BNP measurement for identification of such patients, receiver operating characteristic analysis was performed. The optimal threshold for identification was a BNP concentration of 50 pg/ml with sensitivity of 89.7% and specificity of 95.7%. The area under the receiver operating characteristic curve was 0.970. The positive and negative predictive values at the cutoff level were 44.3% and 99.6%, respectively.

Conclusion: Measurement of plasma BNP concentration is a very efficient and cost effective mass screening technique for identifying patients with various cardiac abnormalities regardless of aetiology and degree of LV systolic dysfunction that can potentially develop into obvious heart failure and carry a high risk of a cardiovascular event.

Citing Articles

Artificial Intelligence-Enabled Electrocardiography Detects B-Type Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide.

Liu P, Lin C, Lin C, Fang W, Lee C, Wang C Diagnostics (Basel). 2023; 13(17).

PMID: 37685262 PMC: 10487184. DOI: 10.3390/diagnostics13172723.


Biomarker Development in Cardiology: Reviewing the Past to Inform the Future.

Kott K, Bishop M, Yang C, Plasto T, Cheng D, Kaplan A Cells. 2022; 11(3).

PMID: 35159397 PMC: 8834296. DOI: 10.3390/cells11030588.


Application of high-performance magnetic nanobeads to biological sensing devices.

Kabe Y, Sakamoto S, Hatakeyama M, Yamaguchi Y, Suematsu M, Itonaga M Anal Bioanal Chem. 2019; 411(9):1825-1837.

PMID: 30627798 PMC: 6453870. DOI: 10.1007/s00216-018-1548-y.


NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department.

Holl M, van den Bos E, van Domburg R, Fouraux M, Kofflard M Clin Cardiol. 2018; 41(3):400-405.

PMID: 29480582 PMC: 6489738. DOI: 10.1002/clc.22883.


Intervention for Varicose Veins of Lower Extremities Lowers the Brain Natriuretic Peptide Values in Varicose Vein Patients.

Tamura K Ann Vasc Dis. 2017; 10(2):115-118.

PMID: 29034036 PMC: 5579778. DOI: 10.3400/avd.oa.16-00102.


References
1.
Maron B, Shen W, Link M, EPSTEIN A, Almquist A, Daubert J . Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(6):365-73. DOI: 10.1056/NEJM200002103420601. View

2.
McDonagh T, Morrison C, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray J . Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997; 350(9081):829-33. DOI: 10.1016/S0140-6736(97)03033-X. View

3.
Smith H, Pickering R, Struthers A, Simpson I, Mant D . Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ. 2000; 320(7239):906-8. PMC: 27331. DOI: 10.1136/bmj.320.7239.906. View

4.
Rossi A, Enriquez-Sarano M, Burnett Jr J, Lerman A, Abel M, Seward J . Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000; 35(5):1256-62. DOI: 10.1016/s0735-1097(00)00515-5. View

5.
Luchner A, Burnett Jr J, Jougasaki M, Hense H, Heid I, Muders F . Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000; 18(8):1121-8. DOI: 10.1097/00004872-200018080-00018. View